Next Article in Journal
Game Analysis on the Evolution of Decision-Making of Vaccine Manufacturing Enterprises under the Government Regulation Model
Previous Article in Journal
Seasonal Influenza Vaccination and Recommendation: The Difference between General Practitioners and Public Health Workers in China
Previous Article in Special Issue
Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus
Open AccessReview

Current Status of Zika Virus Vaccines: Successes and Challenges

by Aryamav Pattnaik 1,2,†, Bikash R. Sahoo 1,2,† and Asit K. Pattnaik 1,2,*
1
School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
2
Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Vaccines 2020, 8(2), 266; https://doi.org/10.3390/vaccines8020266
Received: 8 May 2020 / Revised: 27 May 2020 / Accepted: 28 May 2020 / Published: 31 May 2020
(This article belongs to the Special Issue Update on Flavivirus Vaccines)
The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in adults. The unprecedented nature of the epidemic and serious diseases associated with the viral infections prompted the global research community to understand the immunopathogenic mechanisms of the virus and rapidly develop safe and efficacious vaccines. This has led to a number of ZIKV vaccine candidates that have shown significant promise in human clinical trials. These candidates include nucleic acid vaccines, inactivated vaccines, viral-vectored vaccines, and attenuated vaccines. Additionally, a number of vaccine candidates have been shown to protect animals in preclinical studies. However, as the epidemic has waned in the last three years, further development of the most promising vaccine candidates faces challenges in clinical efficacy trials, which is needed before a vaccine is brought to licensure. It is important that a coalition of government funding agencies and private sector companies is established to move forward with a safe and effective vaccine ready for deployment when the next ZIKV epidemic occurs. View Full-Text
Keywords: Zika virus; vaccine platforms and vaccine candidates; correlates of protection; immunoinformatics; ADE Zika virus; vaccine platforms and vaccine candidates; correlates of protection; immunoinformatics; ADE
Show Figures

Figure 1

MDPI and ACS Style

Pattnaik, A.; Sahoo, B.R.; Pattnaik, A.K. Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines 2020, 8, 266.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop